C

Curie Oncology | Mount Elizabeth Novena Specialist Centre

Research site
(Unclaimed)
Location
38 Irrawaddy Road, #08-21/29/30, Mount Elizabeth Novena Specialist Centre, Singapore, Central Singapore, Singapore

Site insights

Top conditions

Top treatments

Pembrolizumab
Sacituzumab
BAY2927088
Bevacizumab
Tiragolumab
Abemaciclib
Platinum
Domvanalimab
Nivolumab
Atezolizumab

Parent organization

This site is a part of Curie Oncology

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

10 of 10 total trials

A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (IMbrave152) (SKYSCRAPER-14)

The purpose of this study is to assess the efficacy and safety of tiragolumab, an anti-TIGIT monoclonal antibody, when administered in combination wi...

Enrolling
Carcinoma, Hepatocellular
Drug: Tiragolumab
Other: Placebo
Locations recently updated

This is a Phase II, randomized, blinded, active-controlled, global, multicenter study designed to evaluate the safety and efficacy of lomvastomig and...

Active, not recruiting
Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Drug: Nivolumab
Drug: Lomvastomig

This study is being done to find out if zanidatamab, when given with chemotherapy plus or minus tislelizumab, is safe and works better than trastuzum...

Enrolling
Gastroesophageal Adenocarcinoma
Gastric Neoplasms
Drug: Tislelizumab
Drug: Capecitabine

Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called hu...

Begins enrollment this month
HER2 Mutation
Advanced Non-small Cell Lung Cancer
Drug: Cisplatin
Drug: Pembrolizumab

The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to ful...

Enrolling
Metastatic Breast Cancer
Drug: Lasofoxifene in combination with abemaciclib
Drug: Fulvestrant in combination with abemaciclib

Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC), a group of lung cancers that have spre...

Enrolling
EGFR Mutation
HER2 Mutation
Drug: BAY2927088_formulation A
Drug: BAY2927088_formulation B_2

This is a Phase 3, multicenter, open-label, randomized study of nemvaleukin in combination with pembrolizumab versus protocol-specific Investigator's...

Enrolling
Primary Peritoneal Cancer
Fallopian Tube Cancer
Biological: Pembrolizumab
Biological: Nemvaleukin

The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versu...

Enrolling
Triple Negative Breast Cancer
PD-L1 Positive
Drug: Pembrolizumab
Drug: Paclitaxel

The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) versus treatment of phy...

Enrolling
Triple Negative Breast Cancer
PD-L1 Negative
Drug: Sacituzumab Govitecan-hziy
Drug: Paclitaxel

This randomized phase 2 open-label study will evaluate the safety and efficacy of zimberelimab (AB122) monotherapy, domvanalimab (AB154) in combinati...

Active, not recruiting
Squamous Non Small Cell Lung Cancer
Nonsquamous Non Small Cell Lung Cancer
Drug: Zimberelimab
Drug: Domvanalimab

Trial sponsors

Bayer logo
Gilead Sciences logo
Roche logo
Arcus Biosciences logo
Jazz Pharmaceuticals logo
M
S

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems